American oncology company Oncternal Therapeutics is to wind down operations after announcing the sale of its main drug ...

Zanzalintinib plus Tecentriq significantly improved overall survival versus Stivarga in previously treated metastatic ...

Discover which therapies are expected to grab the HER2-low cancers market share @ HER2-low Cancers Market Report The HER2-low ...

Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory small molecule therapy that can cross the blood-brain barrier may be attractive ...

These mechanisms are linked ... rich repeat kinase 2) promote α-syn phosphorylation and impair autophagy. Oxidative stress is worsened by MAO-B (monoamine oxidase B), which produces toxic byproducts ...

CARDIFF, UNITED KINGDOM / ACCESS Newswire / June 18, 2025 / When it comes to type 1 diabetes, treating this chronic condition ...

The Met receptor tyrosine kinase is the prototypic member of a small subfamily of growth factor receptors that when activated induce mitogenic, motogenic, and morphogenic cellular responses. The ...

Each receptor subunit within the dimeric complex then cross-phosphorylates tyrosine residues in the activation loop (A-loop) region of the kinase domain of its neighbor, removing a physical ...

Blossomhill Therapeutics Inc. has synthesized new indazole-based macrocyclic compounds acting as ALK tyrosine kinase receptor inhibitors potentially useful for the treatment of cancer.

Pirtobrutinib, a noncovalent, Bruton tyrosine kinase inhibitor (BTKi), has shown clinical efficacy and a favorable safety profile. BRUIN CLL-321 was an open-label, randomized phase III study conducted ...

The well-studied NF-κB signaling system is a key mediator of the inflammatory response. Large-scale sequencing studies in ...